Neumora Therapeutics is trading 5.87% lower at $0.38 amid continued weakness following recent declines.
- Available reporting identifies no new company announcement explaining the October 23 move.
- A report noted the earlier navacaprant trial failure, but that prior news does not establish the cause of this morning’s decline.
- Supplied market indicators are mixed and do not clearly explain the move.